D-PLEX-100
PDUFASurgical site infection
Approval decisionStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| D-PLEX-100 | Surgical site infection | PDUFA | Nov 28, 2026 | — |
Upcoming milestones
Surgical site infection
Approval decisionCompany profile
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.